Skip to main content

Table 1 Baseline characteristics of study participants, overall and stratified according to whether they developed a NADC during prospective follow-up

From: Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: a cohort study

  All patients Developed a NADC
   Yes No
Total number   41746 (100.0) 880 (100.0) 40866 (100.0)
Gender*, n (%) Male 30572 (73.2) 708 (80.5) 29864 (73.1)
  Female 11143 (26.7) 172 (19.6) 10971 (26.9)
Age (years) Median (IQR) 39 (33, 46) 47 (41, 56) 39 (33, 46)
Mode of HIV acquisition, n (%) Men having sex with men 18251 (43.7) 408 (46.4) 17843 (43.7)
Injection drug user 6075 (14.6) 153 (17.4) 5922 (14.5)
  Heterosexual 14621 (35.0) 256 (29.1) 14365 (35.2)
  Other/unknown 2799 (6.7) 63 (7.2) 2736 (6.7)
Ethnic group, n (%) White 20870 (50.0) 479 (54.4) 20391 (49.9)
  Black 2866 (6.9) 27 (3.1) 2839 (7.0)
  Other 838 (2.0) 11 (1.3) 827 (2.0)
  Unknown/not collected 17172 (41.1) 363 (41.3) 16809 (41.1)
BMI (kg/m2), n (%) <18 1241 (3.0) 39 (4.4) 1202 (2.9)
  ≥18, ≤26 24674 (59.1) 521 (59.2) 24153 (59.1)
  >26, ≤30 4751 (11.4) 99 (11.3) 4652 (11.4)
  >30 1643 (3.9) 43 (4.9) 1600 (3.9)
  Unknown 9437 (22.6) 178 (20.2) 9259 (22.7)
CD4 count (cells/mm3) Median (IQR) 434 (282, 620) 393 (235, 583) 435 (284, 621)
Nadir CD4 count (cells/m3) Median (IQR) 223 (97, 377) 144 (50, 290) 225 (99, 379)
HIV RNA (log10 copies/ml) Median (IQR) 2.3 (1.7, 4.3) 1.7 (1.7, 3.9) 2.3 (1.7, 4.3)
Prior NADC, n (%)   585 (1.4) 48 (5.5) 537 (1.3)
Prior ADC, n (%)   2436 (5.8) 91 (10.3) 2345 (5.7)
Smoking status, n (%) Current Smoker 15526 (37.2) 381 (43.3) 15145 (37.1)
  Ex-smoker 8121 (19.5) 226 (25.7) 7895 (19.3)
  Never smoked 10227 (24.5) 151 (17.2) 10076 (24.7)
  Unknown 7872 (18.9) 122 (13.9) 7750 (19.0)
HCV positive, n (%) 4431 (10.6) 105 (11.9) 4326 (10.6)
HBV positive, n (%) 1751 (4.2) 56 (6.4) 1695 (4.2)
Any use of ARV, n (%) 27778 (66.5) 718 (81.6) 27060 (66.2)
  1. *Information on gender is missing for 31 participants.